Dados B3 › EKTR4 × CPFE3
EKTR4 × CPFE3
Indicators
Each row uses the most recent year in which BOTH companies have the figure, and says which year that is. A cell with ! carries a caveat — hover to read it. We do not name a winner: that would be a recommendation, and this site does not give any.
| indicator | EKTR4 | CPFE3 | year |
|---|---|---|---|
| ROE | 47.3%! | 25.4% | 2025 |
| ROIC | 18.4% | 16.2% | 2025 |
| ROA | 7.6% | 7.3% | 2025 |
| Gross margin | 27.8% | 31.8% | 2025 |
| EBIT margin | 22.8% | 24.9% | 2025 |
| Net margin | 9.6% | 12.9% | 2025 |
| Net debt/EBITDA | 2.88x | 1.94x | 2025 |
| Current ratio | 1.12x | 0.93x | 2025 |
| Revenue growth (1y) | 7.0% | 4.1% | 2025 |
| Revenue growth (5y CAGR) | 7.9% | 7.5% | 2025 |
| Piotroski F-Score | 5/9 | 6/9 | 2025 |
Point-in-time multiples
Priced at the first session on or after the day each filing became public — never the period close.
| indicator | EKTR4 | CPFE3 | year |
|---|---|---|---|
| P/E | 8.09x | 9.86x | 2025 |
| P/B | 3.80x | 2.41x | 2025 |
| EV/EBITDA | 5.73x | 5.97x | 2025 |
| FCF yield | — | 12.5% | 2025 |
Numbers on this page are live. Data version 2026-09-01-supressao-declarada · page generated 2026-09-09 12:36 UTC. If this does not match /saude, you are reading a cached copy.
Sources: CVM (open data, ODbL) and B3 (COTAHIST). Not affiliated with B3 or the CVM. Not investment advice.